Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 15;20:103. doi: 10.1186/s12876-020-01253-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — Dynamic expression of α4β1 integrin on CD4⁺ T cells in the peripheral blood of patients with UC treated with vedolizumab. a Timeline of vedolizumab treatment (T1–5) with representative flow cytometry and clinical data. Flow cytometry of integrin expression on CD4⁺ T-cells in the peripheral blood was performed before T1 and T3. Clinical response was determined at T5. Representative flow cytometric and clinical data from a responder to vedolizumab (upper panels) and a non-responder to vedolizumab (lower panels) are shown. b Left panel: Difference in the expression of α4β1 integrin on CD4⁺ T cells in the peripheral blood between week 0 (T0) and week 6 (T3) of vedolizumab treatment as determined by flow cytometry (n = 26; 18 responders, 8 non-responders). Statistical comparison with two-tailed Mann-Whitney test. Right panel: Receiver-operator-characteristic (ROC) analysis for prediction of clinical response to vedolizumab treatment by changes in α4β1 expression between week 0 and week 6. Significance level (left) and p-value (right) are indicated. MCS – Mayo clinical subscore